Events After the Reporting Period - Additional Information (Details)
$ / shares in Units, € in Thousands |
|
2 Months Ended |
12 Months Ended |
|
|
|
Jan. 28, 2022
USD ($)
$ / shares
shares
|
Feb. 28, 2022
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Dec. 31, 2020
USD ($)
$ / shares
shares
|
Feb. 10, 2022
EUR (€)
|
Jan. 31, 2022
SFr / shares
shares
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Notes issued, original issue discount |
|
|
$ 2,128,000
|
|
|
|
| Treasury Shares [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Number of shares issued | shares |
|
|
5,265,203
|
3,608,291
|
|
|
| Potential Ordinary Share Transactions [Member] | Theramex Licensing Agreement [Member] | Top of range [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Upfront and milestone payments | € |
|
|
|
|
€ 72,750
|
|
| Potential Ordinary Share Transactions [Member] | Tranche two [Member] | JGB Management, Inc [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Notes issued |
$ 10,500,000
|
|
|
|
|
|
| Notes issued, original issue discount |
$ 975,000
|
|
|
|
|
|
| Debt conversion price per common share | $ / shares |
$ 1.66
|
|
|
|
|
|
| Number of warrants issued to purchase common stock | shares |
1,018,716
|
|
|
|
|
|
| Warrant to purchase common share, exercise price | $ / shares |
$ 1.87
|
|
|
|
|
|
| Weighted average share price | $ / shares |
$ 3.00
|
|
|
|
|
|
| Exchange payment of notes issued |
$ 1,250,000
|
|
|
|
|
|
| Proceeds from issue of bonds, notes and debentures |
8,275,000
|
|
|
|
|
|
| Waiver payment of notes issued |
$ 1,250,000
|
|
|
|
|
|
| Potential Ordinary Share Transactions [Member] | Signing Milestones [Member] | Theramex Licensing Agreement [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Upfront and milestone payments | € |
|
|
|
|
5,000
|
|
| Potential Ordinary Share Transactions [Member] | Development and Commercial Milestones [Member] | Theramex Licensing Agreement [Member] | Top of range [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Upfront and milestone payments | € |
|
|
|
|
13,750
|
|
| Potential Ordinary Share Transactions [Member] | Sales-Based Milestones [Member] | Theramex Licensing Agreement [Member] | Top of range [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Upfront and milestone payments | € |
|
|
|
|
€ 54,000
|
|
| Common shares [Member] | Potential Ordinary Share Transactions [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Number of shares issued | shares |
|
|
|
|
|
23,400,000
|
| Par value of shares | SFr / shares |
|
|
|
|
|
SFr 0.0769
|
| ATM [Member] | Treasury Shares [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Number of shares issued | shares |
|
|
15,933,420
|
5,995,897
|
|
|
| Share price | $ / shares |
|
|
$ 3.28
|
$ 2.82
|
|
|
| Proceeds from sale of treasury shares |
|
|
$ 53,700,000
|
$ 16,900,000
|
|
|
| ATM [Member] | Potential Ordinary Share Transactions [Member] | Treasury Shares [Member] |
|
|
|
|
|
|
| Disclosure Of Nonadjusting Events After Reporting Period [Line Items] |
|
|
|
|
|
|
| Number of shares issued | shares |
|
2,859,253
|
|
|
|
|
| Share price | $ / shares |
|
$ 1.61
|
|
|
|
|
| Proceeds from sale of treasury shares |
|
$ 4,600,000
|
|
|
|
|